Krystexxa (generic name metoclopramide in its injectable form) is an antiemetic and gastro‑motility agent used primarily to prevent nausea and vomiting after surgery (post‑operative) and in certain other clinical situations (e.g., chemotherapy‑induced nausea, acute pancreatitis, or when rapid gastric emptying is needed).
Key Points
| Feature |
Details |
| Drug class |
Dopamine D₂ receptor antagonist; also has 5‑HT₃ and 5‑HT₄ receptor activity. |
| Form |
Intramuscular (IM) or intravenous (IV) solution; marketed as Krystexxa®. |
| Approved uses |
• Prevention of postoperative nausea and vomiting (PONV)
• Treatment of acute nausea and vomiting of any cause when other therapies have failed. |
| Typical adult dose |
• IM or IV: 10 mg (single dose).
• If vomiting persists after 30 min, a second 10 mg dose may be given.
• Maximum 20 mg per 24 h. |
| Special populations |
• Pregnancy: Category B (no proven risk in humans).
• Breastfeeding: limited data; use only if benefits outweigh risks.
• Elderly: use same dosing; monitor for extrapyramidal side effects. |
| Contraindications |
• Known hypersensitivity to metoclopramide.
• Active or recent malignant cerebral tumor, seizures, or serious cardiac arrhythmias (unless cleared by a cardiologist). |
| Precautions |
• Monitor for extrapyramidal symptoms (tremor, dystonia, Parkinson‑like rigidity).
• Watch for tardive dyskinesia with long‑term use (>2–3 weeks).
• Use cautiously in patients with hepatic or renal impairment (dose adjustments may be needed). |
| Common side effects |
– Nausea, dizziness, drowsiness, headache.
– Rare: severe motor side effects (dystonia, akathisia, Parkinsonism).
– Rare: neuroleptic malignant syndrome. |
| Drug interactions |
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can increase metoclopramide levels.
• Antipsychotics may potentiate extrapyramidal symptoms.
• Anticonvulsants (e.g., carbamazepine) may lower its plasma levels. |
How It Works
- Blocking dopamine (D₂) receptors in the chemoreceptor trigger zone (CTZ) of the brain reduces nausea signals.
- Stimulation of 5‑HT₄ receptors in the GI tract enhances motility, helping food move through the stomach faster.
- The dual action makes it effective for both central (nausea) and peripheral (delayed gastric emptying) problems.
Practical Tips for Clinicians
- Timing: Administer 30 minutes before the anticipated start of surgery or before the first dose of chemotherapy.
- Route: IM is preferred for postoperative settings; IV may be chosen when rapid onset is required.
- Monitoring: Assess for motor side effects at 2–3 hour intervals after dosing.
- Patient Education: Advise patients to report any sudden involuntary movements or stiffness.
- Storage: Keep in a refrigerator (2–8 °C); protect from light; do not use after the expiration date.
Quick FAQ
Q: Is Krystexxa the same as regular metoclopramide tablets?
A: It contains the same active ingredient but is specifically formulated for IM/IV use. Oral metoclopramide is available as tablets and suspension.
Q: Can it be used for migraine nausea?
A: It may be prescribed for migraines, but it is not FDA‑approved for that indication. In practice, many clinicians use it off‑label for refractory migraine nausea.
Q: How long does the effect last?
A: The anti‑emetic effect typically lasts 4–6 hours; the pro‑kinetic benefit may persist longer but depends on the underlying GI condition.
Q: Are there any serious long‑term risks?
A: Prolonged use (more than 2–3 weeks) can lead to tardive dyskinesia—a permanent involuntary movement disorder. Hence, Krystexxa is usually a short‑term rescue or preventative agent.
Bottom line
Krystexxa is a highly effective, short‑term solution for preventing or treating nausea and vomiting when oral medications are inadequate or when rapid onset is needed. Its dosing is straightforward, but clinicians must remain vigilant for motor side effects, especially with repeated dosing. If you’re a patient or caregiver, discuss any concerns with your prescribing clinician, and report any unusual movements or symptoms immediately.